In this study, we demonstrated that RCC1 knockdown significantly improved the antitumor effects of 5-FU and Doxo in both parental and drug-resistant CRC cell lines and animal models, in vitro and in vivo. This evidence concerns the gene RCC1 and colorectal carcinoma.